Corrigendum to "Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer": [Annals of Oncology 33 (2022) 769-785]

K Van Baelen; T Geukens; M Maetens; V Tjan-Heijnen; C J Lord; S Linn; F-C Bidard; F Richard; W W Yang; R E Steele; S J Pettitt; C Van Ongeval; M De Schepper; E Isnaldi; I Nevelsteen; A Smeets; K Punie; L Voorwerk; H Wildiers; G Floris; A Vincent Salomon; P W B Derksen; P Neven; E Senkus; E Sawyer; M Kok; C Desmedt

doi:10.1016/j.annonc.2022.11.010

Corrigendum to "Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer": [Annals of Oncology 33 (2022) 769-785]

Ann Oncol. 2023 Mar;34(3):326. doi: 10.1016/j.annonc.2022.11.010. Epub 2022 Dec 16.

Authors

K Van Baelen¹, T Geukens², M Maetens³, V Tjan-Heijnen⁴, C J Lord⁵, S Linn⁶, F-C Bidard⁷, F Richard³, W W Yang⁵, R E Steele⁵, S J Pettitt⁵, C Van Ongeval⁸, M De Schepper⁹, E Isnaldi³, I Nevelsteen¹⁰, A Smeets¹⁰, K Punie¹¹, L Voorwerk¹², H Wildiers¹¹, G Floris¹³, A Vincent Salomon¹⁴, P W B Derksen¹⁵, P Neven¹⁶, E Senkus¹⁷, E Sawyer¹⁸, M Kok¹², C Desmedt¹⁹

Affiliations

¹ Laboratory for Translational Breast Cancer Research (LTBCR), Department of Oncology, KU Leuven, Leuven; Department of Gynaecology and Obstetrics, UZ Leuven, Leuven, Belgium.
² Laboratory for Translational Breast Cancer Research (LTBCR), Department of Oncology, KU Leuven, Leuven; Department of General Medical Oncology, UZ Leuven, Leuven, Belgium.
³ Laboratory for Translational Breast Cancer Research (LTBCR), Department of Oncology, KU Leuven, Leuven.
⁴ Department of Medical Oncology Department, Maastricht University Medical Center (MUMC), School of GROW, Maastricht, The Netherlands.
⁵ The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
⁶ Department of Pathology, University Medical Center Utrecht, Utrecht; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁷ Department of Medical Oncology, Institut Curie, UVSQ/Paris-Saclav University, Paris, France.
⁸ Department of Radiology, UZ Leuven, Leuven, Belgium.
⁹ Laboratory for Translational Breast Cancer Research (LTBCR), Department of Oncology, KU Leuven, Leuven; Department of Pathology, UZ Leuven, Leuven, Belgium.
¹⁰ Department of Surgical Oncology, UZ Leuven, Leuven, Belgium.
¹¹ Department of General Medical Oncology, UZ Leuven, Leuven, Belgium.
¹² Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Tumour Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
¹³ Department of Pathology, UZ Leuven, Leuven, Belgium.
¹⁴ Department of Pathology, Institut Curie, Paris, France.
¹⁵ Department of Pathology, University Medical Center Utrecht, Utrecht.
¹⁶ Department of Gynaecology and Obstetrics, UZ Leuven, Leuven, Belgium.
¹⁷ Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.
¹⁸ School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK.
¹⁹ Laboratory for Translational Breast Cancer Research (LTBCR), Department of Oncology, KU Leuven, Leuven. Electronic address: christine.desmedt@kuleuven.be.

PMID: 36529568
DOI: 10.1016/j.annonc.2022.11.010

No abstract available

Publication types

Published Erratum